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Lymph nodes draining progressive tumors contain tumor-sensitized but not functional preeffector
T lymphocytes. These cells can acquire antitumor reactivity after stimulation with tumor cells
and interleukin-2 (IL-2). We demonstrated here that, in the absence of tumor cells, preeffector
cells could be stimulated and expanded by sequential culture with anti-CD3 monoclonal antibody
and IL-2. The adoptive transfer of such activated cells mediated immunologically specific reductions
of established pulmonary metastases. The therapeutic effects could be enhanced by the admin-
istration of IL-2. This activation represents a secondary immune response because effector  cells
could be generated only from tumor-draining but not from normal or adjuvant-stimulated lymph
nodes. Furthermore, treatment of advanced metastases with these cells resulted in prolongation
of survival and cure of the disease. Thus, anti-CD3 may serve as a universal reagent for activating
tumor-sensitized T lymphocytes for cancer therapy. Q  1991 Academic  press,  hc.
INTRODUCTION
The adoptive transfer of immune T lymphocytes into tumor-bearing animals can
mediate the regression of established primary and metastatic tumors (l-3). The most
critical aspect for the successful clinical application of adoptive immunotherapy is the
identification of functional immune cells from cancer patients. Because the putative
immune response during tumor progression is weak, isolation of a sufficient number
of immune effector cells must depend on the ability to boost this reactivity by in vitro
manipulations. Using syngeneic animal tumors, we have recently described a method
whereby lymph node (LN)3 cells draining progressive tumor could be stimulated and
expanded to acquire therapeutic efficacy (3-5). To accomplish this, LN cells had to
be antigenically stimulated by the tumor of origin in the presence of interleukin-2 (IL-
2). These observations have prompted us to evaluate similarly generated tumor-sen-
sitized T lymphocytes for the treatment of humans with advanced cancer. Although
this method is theoretically and technically feasible, the requirement of large numbers
of autologous tumor cells has restricted its application in many cases. Antigenic stim-
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ulation of T lymphocytes involves the T cell receptor (TCR) which is noncovalently
associated with a cluster of low MW proteins commonly referred to as CD3 (6). Con-
siderable evidence indicates that the CD3 structure serves to transduce the activation
signals consequential to the binding of antigen to TCR (7). Indeed, in the absence of
the antigen, mAb reactive to CD3 molecules have been shown to induce T cell pro-
liferation and lymphokine secretion (8, 9). In the present study, we show that tumor-
draining LN cells proliferated when stimulated with an anti-CD3 mAb and subse-
quently cultured in IL-2. More significantly, such activated cells were highly effective
in mediating the immunologically specific regression of established tumor metastases.
MATERIALS AND METHODS
Mice. Female C57BL/6 (B6) mice were obtained from The Jackson Laboratory
(Bar Harbor, ME) and were used at the age of 10 weeks or older.
Tumors. The MCA 106 tumor is a 3-methylcholanthrene-induced fibrosarcoma
syngeneic to B6 mice (10). It was maintained in vivo by serial SC transplantation of
cryopreserved tumor samples and used for the current study in the fourth to seventh
transplantation generation. Other similarly induced MCA 102 and MCA 105 sarcomas
of B6 origin served as specificity controls. Single cell suspensions were prepared from
solid tumors by digestion in 40 ml of HBSS (GIBCO, Grand Island, NY) containing
4 mg of DNase,  40 mg of collagenase, and 100 U of hyaluronidase (Sigma Chemical
Co., St. Louis, MO) for 3 hr at room temperature.
For initiating solid tumor growth, B6 mice were inoculated SC in the footpad with
8-10 X lo5 viable tumor cells in 0.05 ml of HBSS. Twelve to 14 days later, when
footpad thickness increased to approximately 8 mm, tumor-draining popliteal LN
were harvested and single cells were prepared mechanically.
Anti-CD3 mAb.  A hamster mAb,  145-2C11,  directed against the CD3-t  chain of
the murine TCR/CD3 complex was produced and kindly provided by Dr. Jeffrey A.
Bluestone, University of Chicago (9). The mAb was harvested as ascites fluid following
inoculation of sublethally irradiated (500 R) DBA/2 mice with the hybridoma cells.
Ab was then partially purified by 50% ammonium sulfate precipitation. The hamster
IgG content of the preparation was determined by ELISA.
IL-2. Human recombinant IL-2 was kindly supplied by the Cetus Corp. (Emeryville,
CA). The biological and biochemical activities of this material have been described
(11). Purified material had a specific activity of 3.0 X lo6 U/mg. In our assay 1 U of
Cetus IL-2 is equivalent to 2-3 U of the standard of the Biological Response Modifiers
Program of the National Cancer Institute.
Activation of LN cells with anti-CD3/ZL-2.  Tumor-draining LN cells were activated
by incubating 6-10 X lo7 cells in a 75-cm2 tissue culture flask containing 30 ml of
complete medium (12) with 1 pg/ml of anti-CD3 at 37°C in a 5% CO2 atmosphere
for 2 days. The cells were harvested, washed, and further cultured at 4-6 X lo5 cells/
well in 2 ml of complete medium containing 10 U/ml of human recombinant IL-2
in 24-well  plates for 3 days. The resulting cells were resuspended in HBSS for adoptive
immunotherapy.
Adoptive immunotherapy. B6 mice were injected iv with 8-10 X lo5 MCA 106
tumor cells suspended in 1.0 ml of HBSS to initiate pulmonary metastases. On Day
3, anti-CD3/IL-2-activated  LN cells were given iv. In most experiments, mice receiving
cells were also given ip injections of IL-2 to enhance the antitumor efficacy of the
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FIG. 1. Proliferative response of tumor-draining LN cells from mice bearing intrafootpad MCA 106
tumors for 14 days. Single cell suspensions prepared from popliteal LN were cultured at 6 X IO’  cells in 30
ml of complete medium containing I pg/ml  of anti-CD3, 10 U/ml of IL-2. or both for 2 days. Harvested
cells were washed and replated in 24-well  culture plates at 6 X IO5  cells/well in the presence of anti-CD3,
IL-2, or both for an additional 3 days. It appeared that stimulation with anti-CD3 followed by expansion
in IL-2 was necessary for maximal proliferation.
transferred cells. Between Days 21 and 27 after tumor induction, the mice were ran-
domized and sacrificed for enumeration of pulmonary tumor nodules as described
(13). Metastatic foci too numerous to count were assigned an arbitrary value of 250
since this was the greatest number of tumor nodules that could be reliably enumerated.
Each treatment group consisted of at least five animals. Statistical analyses were per-
formed by the Wilcoxon  rank sum test. A two-sided P value of ~0.05  was considered
a significant difference between two groups.
In some experiments, mice with advanced pulmonary metastases (10 days after
tumor initiation) were treated with anti-CD3/IL-2-activated  cells in conjunction with
the administration of exogenous IL-2. Therapeutic efficacy was evaluated by the survival
of treated animals.
RESULTS AND DISCUSSION
The therapeutic efficacy of adoptive immunotherapy is proportional to the numbers
of immune effector cells transferred. Therefore, we initially examined the conditions
under which maximal cellular proliferation with concurrent activation of effector cells
could be induced by anti-CD3. Tumor-draining LN cells stimulated with anti-CD3
mAb at a concentration of 1 pg/ml  for 2 days did not result in significant proliferation.
However, these anti-CD3-stimulated cells responded to a low concentration (10 U/
ml) of IL-2. After 3 days in the presence of IL-2, more than a IO-fold increase in cell
numbers was observed (Fig. 1). This cellular proliferation was not induced when LN
cells were cultured in either anti-CD3 or IL-2 alone for a total of 5 days. In addition,
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TABLE 1
Conditions and Requirements for Generation of Antitumor Effector  Cells
by the Method of Anti-CD3/IL-2  Activation
Adoptive immunotherapy





Mean No. of pulmonary
MCA 106 metastases
(SEW








+ 250 240 (9)
Anti-CD3/IL-2 + 6 (lib 2 (lJb
Con A/IL-2 + 132 (17) 191 (33)
IL-2/IL-2 + 190 (30)
Anti-CD3/IL-2 + 216 (22)
Anti-CD3/IL-2 + 205 (29) 237 (11)
0 Popliteal LN cells draining the progressively growing MCA 106 tumors for 12 days were cultured in 1
&ml of anti-CD3, 2 &ml of Con A, or 10 U/ml of IL-2 for 2 days followed by expansion in 10 U/ml of
IL-2 for 3 days. Normal mesenteric LN cells and LN cells draining injections of 100 wg  of C. parvum for
12 days were activated by anti-CD3/IL-2.  All cells were tested for in vivo antitumor effects in adoptive
immunotherapy of 3-day  established pulmonary MCA 106 metastases. Each mouse received iv 6 X lo6
activated cells. IL-2 (15,000 U, twice daily) was given ip from Day 3 to Day 6.
b Significantly different when compared with groups receiving no treatment or IL-2 only.
the proliferation response was not enhanced even if both anti-CD3 and IL-2 were
present during the two stages of culture.
By phenotype analysis, freshly harvested tumor-draining LN contained 37 f 9%
Thy-l+ lymphocytes with 18 f 2% of CD4+  (L3T4+)  and 14 + 1% of CD8+  (Lyt-2+)
cells. There was little or no detectable IL-2 receptor (IG2R) present on these cells.
However, after 2 days of activation with antKD3, recovered cells were virtually all
Thy-l+ (296%) and consisted of 32 k 6% CD4+  and 59 + 8% CD8+  cells. At this
stage, IL-2R expression became evident as revealed by flow cytometry. The greatest
cellular proliferation occurred when anti-CD3-stimulated LN cells were cultured in
IL-2 for an additional 3 days. During this time, cell numbers doubled every 24 hr.
CD8+  cells appeared to respond more vigorously than CD4+  cells because the IL-2-
expanded cell population contained 75 + 9% CD8+  and 24 + 7% CD4+  cells.
The antitumor efficacy of such activated cells was first examined in the adoptive
immunotherapy of 3-day established pulmonary MCA 106 metastases. In several pre-
liminary experiments, the transfer of 2 X lo7 activated cells alone was capable of
reducing the numbers of pulmonary metastases from 2250 in the nontreated groups
to an average of 4 +-  2. The antitumor reactivity of these cells could be further enhanced
by the concomitant administration of exogenous IL-2 (15,000 U, twice daily) for 4
days. In the same experiments, the transfer of as few as 6 X lo6 activated cells in
conjunction with IL-2 injections reduced pulmonary metastases to 2 f 1. Since treat-
ment with IL-2 alone did not have any therapeutic effects, these results suggest that
the administered IL2  acted on the transferred cells probably by promoting their survival
and function in vivo.
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TABLE 2
Specificity of Adoptive Immunotherapy Mediated by Anti-CD3/IL-2-Activated  Tumor-Draining LN Cells
Treatment
Source of draining LN” IL-2
Mean No. pulmonary metastases (SEM)’
MCA 106 MCA 105 MCA 102
-- 240 (IO) 250 250
+ 216 (19) 250 250
MCA 1 0 6 + 2 (1)’ 250 217 (28)
MCA 105 + 246 (4)
MCA 1 0 2 + 250
’ Popliteal LN cells draining the progressively growing MCA tumors in the footpad for 14 days were
activated by anti-CD3/1L-2  as described in Table I.
b Pulmonary metastases were induced by iv injections of 3 X 10’  (MCA 102)  3 X 10’  (MCA 105)  or
lo6 (MCA 106) tumor cells. The protocol for adoptive immunotherapy was as described in Table 1. except
that 2 x IO’  activated cells were given to each mouse.
” Significantly different when compared with groups receiving no treatment or IL-2 only.
The anti-CD3 mAb has reactivity toward all T lymphocytes and we found that the
activation of normal LN cells induced an equivalent cell proliferation. Therefore, we
examined the in vivo and in vitro conditions and requirements that were necessary
for the generation of therapeutically effective cells. Normal mesenteric LN cells and
cells prepared from popliteal LN draining intrafootpad injections of 100 pg  of Cory-
nebacterium  aarvum  (Burroughs Wellcome  Co., Research Triangle Park, NC) were
activated by anti-CD3 and IL-2 for 5 days. These cells as well as anti-CD3/IL-2-
activated MCA 106 tumor-draining LN cells were tested for in vivo antitumor effects
(Table 1). Neither activated normal LN cells nor adjuvant-stimulated LN cells dem-
onstrated significant antitumor effects. These results clearly indicate the requirement
of a critical sensitization during progressive tumor growth. On the other hand, the
transfer of as many as 5 X 10’ freshly harvested tumor-draining LN cells with or
without concomitant IL-2 treatment did not demonstrate antitumor reactivity (data
not shown). Thus, the in vitro activation with anti-CD3/IL-2  represents a secondary
immune response which activates previously sensitized preeffector cells. This is in
contrast to the mitogenic effects of anti-CD3 which do not exhibit antigenic specificity.
Also examined were conditions under which preeffector cells could develop into ther-
apeutic effector cells in vitro. In this part of the experiment, MCA 106 tumor-draining
LN cells were cultured in anti-CD3 (1 pg/ml),  Con A (2 pg/ml),  or IL-2 (10 U/ml)
for 2 days and harvested cells were expanded in IL-2 ( 10 U/ml) for 3 days. As also
presented in Table 1,  cells activated by Con A or cultured in IL-2 only failed to develop
into antitumor effector cells. It thus appears that the interaction of anti-CD3 with
preeffector cells, although not antigenically specific, provides essential signals to trigger
their maturation into functional therapeutic cells. In previous studies (4, 5), we found
that tumor-draining LN cells could be stimulated in vitro by specific tumor cells to
differentiate into immune effector cells. It is therefore likely that anti-CD3 mimics the
antigenic stimulation in the secondary activation.
Numerous reports have demonstrated that the interaction of anti-CD3 with T lym-
phocytes induced proliferation, secretion of various lymphokines/cytokines, up-reg-
ulation of the expression of IL-2R,  and/or the generation of cytotoxic effector cells (8,
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FIG. 2. Adoptive immunotherapy of mice with advanced pulmonary MCA 106 metastases. This figure
summarizes combined results of two independent but identically designed experiments. Pulmonary metastases
were induced by the iv injection of lo6 MCA 106 tumor cells. Ten days later, when metastatic nodules were
clearly visible, therapy was instituted by iv infusion of 8 X 10’ anti-CD3/IL-2-activated  tumor-draining LN
cells (prepared as described in Table 1). The dose of IL-2 was 15,000 U given ip twice daily, for 5 days.
Treatment with activated LN cells and IL-2 resulted in a significant prolongation of survival (P i 0.05,
Wilcoxon  rank sum test).
9, 14). None of these reactivities represent antigen-specific events, probably due to the
ubiquitous presence of CD3 molecules on all T lymphocytes. However, it is also
known that anti-CD3 is capable of activating specific cytotoxic T cells in the absence
of nominal antigens (15). The results of the preceding experiments thus suggest that
an element of anti-CD3-T cell interactions might reflect stimulation of tumor antigen-
sensitized preeffector cells. We therefore examined the specificity of adoptive immu-
notherapy mediated by anti-CD3/IL-2-activated cells. In the experiment summarized
in Table 2, it is clear that effector  cells generated from MCA 106 tumor-draining LN
cells mediated the regression of the MCA 106 tumor but not that of the antigenically
distinct MCA 102 or MCA 105 tumor. At the effector  cell level, the regression of the
MCA 106 tumor could be mediated only by cells generated from MCA 106 but not
MCA 102 or MCA 105 tumor-draining LN. Moreover, anti-CD3/IL-2-activated  MCA
102 and MCA 105 tumor-draining LN cells mediated the regression of their respective
tumors (data not shown). Therefore, the specificity of antitumor reactivity was ap-
parently determined at the preeffector cell level, i.e., during progressive tumor growth.
These results are consistent with the notion that the anti-CD3/IL-2 activation is a
secondary immune reaction. In this situation, the anti-CD3 mAb serves a function
similar to that of the specific antigen for activation of immunologically committed
preeffector T cells. Despite their ability to mediate tumor regression in vivo, we have
consistently found that the effector  cells did not exhibit cytotoxic effects in vitro in
the standard 4-hr chromium release assay (data not shown). This finding is intriguing
and has prompted us to investigate the mechanisms of tumor eradication mediated
by these noncytolytic effector  cells.
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The adoptive immunotherapy experiments described thus far involved the treatment
of 3-day established pulmonary metastases. At this stage of disease, metastases were
only microscopically evident, To further evaluate the therapeutic efficacy of anti-CD31
IL-2-activated cells, mice with advanced metastases were treated with these cells. Pul-
monary metastases were initiated by iv injection of mice with MCA 106 tumor cells.
Adoptive immunotherapy was instituted 10 days later when tumor nodules on the
surface of the lung became clearly visible. The pooled results of two independent
experiments are summarized in Fig. 2. Mice that were not treated or that were treated
for 5 days with IL-2 (15,000 U, twice daily) succumbed to the growing tumor with
median survival times of 30 and 3 1 days, respectively. Mice treated with 8 X 10’  anti-
CD3/IL-2-activated  tumor-draining LN cells plus exogenous IL-2 showed a prolonged
median survival time of 50 days, and 7 of 20 treated animals were tumor-free for >90
days. The high therapeutic efficacy of these activated cells provides a rationale for the
use of similarly activated cells from cancer patients for adoptive immunotherapy.
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